AlphaTON Capital (ATON) Registration Filing summary

Company overview and business model

• Operates two primary business lines: digital asset investment (focused on TON token) and immune-oncology research and development.

• Entered the digital asset sector in 2025, allocating 99% of recent private placement proceeds to TON token acquisition, with the remainder for legacy biotech operations.

• Digital asset strategy centers on holding TON as a core treasury asset, leveraging its integration with Telegram's large user base.

• Immune-oncology business seeks to develop first-in-class therapies targeting checkpoint resistance in cancer, but faces capital constraints and is exploring strategic alternatives.

• Incorporated in the British Virgin Islands, with a history of business pivots and recent rebranding to reflect the digital asset focus.

Financial performance and metrics

• Raised approximately $36.2 million in gross proceeds from a private placement in September 2025.

• Acquired an initial $15 million tranche of TON token for its treasury.

• As of October 20, 2025, had 6,349,197 Ordinary Shares outstanding.

Use of proceeds and capital allocation

• 99% of net cash from the private placement allocated to TON token purchases; $4 million reserved for legacy immune-oncology business.

• No proceeds from the current offering will go to the company; all proceeds go to the selling shareholder.